SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): Creating a Repository of Deeply Phenotyped Contemporary Multiple Sclerosis Cohorts

Overview

Journal Mult Scler

Publisher Sage Publications

Specialty Neurology

Date 2017 Aug 30

PMID 28847219

Citations 14

Authors

Riley Bove

Tanuja Chitnis

Bruce Ac Cree

Mar Tintore

Yvonne Naegelin

Bernard Mj Uitdehaag

Ludwig Kappos

Samia J Khoury

Xavier Montalban

Stephen L Hauser

Howard L Weiner

Affiliations

Soon will be listed here.

Abstract

Background: There is a pressing need for robust longitudinal cohort studies in the modern treatment era of multiple sclerosis.

Objective: Build a multiple sclerosis (MS) cohort repository to capture the variability of disability accumulation, as well as provide the depth of characterization (clinical, radiologic, genetic, biospecimens) required to adequately model and ultimately predict a patient's course.

Methods: Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) is an international multi-center, prospectively enrolled cohort with over a decade of comprehensive follow-up on more than 1000 patients from two large North American academic MS Centers (Brigham and Women's Hospital (Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB; BWH)) and University of California, San Francisco (Expression/genomics, Proteomics, Imaging, and Clinical (EPIC))). It is bringing online more than 2500 patients from additional international MS Centers (Basel (Universitätsspital Basel (UHB)), VU University Medical Center MS Center Amsterdam (MSCA), Multiple Sclerosis Center of Catalonia-Vall d'Hebron Hospital (Barcelona clinically isolated syndrome (CIS) cohort), and American University of Beirut Medical Center (AUBMC-Multiple Sclerosis Interdisciplinary Research (AMIR)).

Results And Conclusion: We provide evidence for harmonization of two of the initial cohorts in terms of the characterization of demographics, disease, and treatment-related variables; demonstrate several proof-of-principle analyses examining genetic and radiologic predictors of disease progression; and discuss the steps involved in expanding SUMMIT into a repository accessible to the broader scientific community.

Citing Articles

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study.

Gonzalez-Martinez A, Bose G, Lokhande H, Saxena S, Healy B, Polgar-Turcsanyi M J Neuroinflammation. 2023; 20(1):136.

PMID: 37264432 PMC: 10233999. DOI: 10.1186/s12974-023-02816-8.

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis.

Howlett-Prieto Q, Oommen C, Carrithers M, Wunsch 2nd D, Hier D Front Digit Health. 2023; 4:1063264.

PMID: 36714613 PMC: 9874946. DOI: 10.3389/fdgth.2022.1063264.

Temporal trends of multiple sclerosis disease activity: Electronic health records indicators.

Liang L, Kim N, Hou J, Cai T, Dahal K, Lin C Mult Scler Relat Disord. 2022; 57:103333.

PMID: 35158446 PMC: 8849591. DOI: 10.1016/j.msard.2021.103333.

The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS).

Rammohan K, Halper J, Lang S, Murphy S, Patton L, Goodman C Int J MS Care. 2022; 23(6):269-275.

PMID: 35035298 PMC: 8745232. DOI: 10.7224/1537-2073.2021-021.

Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.

Otero-Romero S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, Galan I, Cobo-Calvo A Mult Scler. 2021; 28(6):950-957.

PMID: 34841948 PMC: 9024022. DOI: 10.1177/13524585211053001.

References

Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F . Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008; 15(9):916-21. DOI: 10.1111/j.1468-1331.2008.02241.x. View

Rotstein D, Healy B, Malik M, Chitnis T, Weiner H . Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2014; 72(2):152-8. DOI: 10.1001/jamaneurol.2014.3537. View

Bevan C, Cree B . Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?. JAMA Neurol. 2014; 71(3):269-70. DOI: 10.1001/jamaneurol.2013.5486. View

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore G, Tortorella C . Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009; 66(4):513-20. DOI: 10.1002/ana.21757. View

Patsopoulos N, Barcellos L, Hintzen R, Schaefer C, Van Duijn C, Noble J . Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013; 9(11):e1003926. PMC: 3836799. DOI: 10.1371/journal.pgen.1003926. View

Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J . HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000; 48(2):211-9. View

Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach I, Bucci M . Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014; 76(4):568-80. PMC: 5316412. DOI: 10.1002/ana.24241. View

Houtchens M, Benedict R, Killiany R, Sharma J, Jaisani Z, Singh B . Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007; 69(12):1213-23. DOI: 10.1212/01.wnl.0000276992.17011.b5. View

Butzkueven H, Chapman J, Cristiano E, GrandMaison F, Hoffmann M, Izquierdo G . MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2007; 12(6):769-74. DOI: 10.1177/1352458506070775. View

10.

Patsopoulos N, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J . Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011; 70(6):897-912. PMC: 3247076. DOI: 10.1002/ana.22609. View

11.

Pittock S, Mayr W, McClelland R, Jorgensen N, Weigand S, Noseworthy J . Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology. 2004; 62(4):601-6. DOI: 10.1212/wnl.62.4.601. View

12.

Corvol J, Pelletier D, Henry R, Caillier S, Wang J, Pappas D . Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A. 2008; 105(33):11839-44. PMC: 2504481. DOI: 10.1073/pnas.0805065105. View

13.

Keshavan A, Paul F, Beyer M, Zhu A, Papinutto N, Shinohara R . Power estimation for non-standardized multisite studies. Neuroimage. 2016; 134:281-294. PMC: 5656257. DOI: 10.1016/j.neuroimage.2016.03.051. View

14.

Gourraud P, Henry R, Cree B, Crane J, Lizee A, Olson M . Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014; 76(5):633-42. PMC: 4214886. DOI: 10.1002/ana.24282. View

15.

Cree B, Reich D, Khan O, De Jager P, Nakashima I, Takahashi T . Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol. 2009; 66(2):226-33. PMC: 4334456. DOI: 10.1001/archneurol.2008.541. View

16.

Cohen A, Neema M, Arora A, DellOglio E, Benedict R, Tauhid S . The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging. 2011; 22(2):122-8. PMC: 3128174. DOI: 10.1111/j.1552-6569.2011.00589.x. View

17.

Beecham A, Patsopoulos N, Xifara D, Davis M, Kemppinen A, Cotsapas C . Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013; 45(11):1353-60. PMC: 3832895. DOI: 10.1038/ng.2770. View

18.

Ottoboni L, Keenan B, Tamayo P, Kuchroo M, Mesirov J, Buckle G . An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012; 4(153):153ra131. PMC: 3753678. DOI: 10.1126/scitranslmed.3004186. View

19.

Xia Z, White C, Owen E, Von Korff A, Clarkson S, McCabe C . Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Ann Neurol. 2015; 79(2):178-89. PMC: 4778957. DOI: 10.1002/ana.24560. View

20.

Healy B, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C . HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010; 75(7):634-40. PMC: 2931768. DOI: 10.1212/WNL.0b013e3181ed9c9c. View